10-Q: J&J Q3 Earnings Soar 104% on Talc Reserve Reversal

Johnson & Johnson reported a 104% surge in net earnings for the fiscal nine months ended September 28, 2025, primarily driven by a $7 billion reversal of talc litigation reserves, alongside 5.0% total sales growth.

Summary

• Net earnings for the fiscal nine months ended September 28, 2025, surged by 103.9% to $21.688 billion, compared to $10.635 billion in the prior year.
• Diluted earnings per share (EPS) increased by 104.1% to $8.94 for the fiscal nine months, up from $4.38 in the previous year.
• Worldwide sales grew by 5.0% to $69.629 billion for the fiscal nine months, with operational growth of 4.7%.
• Approximately $7.0 billion of previously accrued talc litigation reserves were reversed following the dismissal of the Red River Bankruptcy Case.
• Innovative Medicine segment sales increased by 4.7% to $44.638 billion, driven by strong performance in Oncology and Neuroscience, but impacted by biosimilar competition for STELARA.
• MedTech segment sales rose by 5.6% to $24.991 billion, with significant contributions from recent acquisitions like Shockwave and Abiomed.
• The worldwide effective income tax rate increased to 21.5% from 16.9% due to the U.S. One Big Beautiful Bill Act (OBBBA), which included a one-time re-measurement cost of approximately $1.0 billion.
• An intention to separate the Orthopaedics business was announced, targeting completion within 18 to 24 months.

Sentiment

Score: 7

Explanation: The significant increase in net earnings and EPS is primarily due to a one-time reversal of talc litigation reserves, which masks more moderate operational sales growth. While acquisitions are contributing positively, the substantial decline in STELARA sales due to biosimilar competition and the increase in total debt are notable concerns. The planned Orthopaedics separation is a strategic move with potential long-term benefits but also execution risks.

Positives

• Net earnings for the fiscal nine months increased by 103.9% to $21.688 billion.
• Diluted EPS grew by 104.1% to $8.94 for the fiscal nine months.
• Worldwide sales increased by 5.0% to $69.629 billion for the fiscal nine months, with operational growth of 4.7%.
• Innovative Medicine segment sales grew by 4.7% operationally, with Oncology sales up 20.6% and Neuroscience sales up 7.2%.
• CARVYKTI sales surged by 89.6% to $1.332 billion for the fiscal nine months.
• DARZALEX sales increased by 21.7% to $10.448 billion for the fiscal nine months.
• SPRAVATO sales grew by 53.0% to $1.193 billion for the fiscal nine months.
• MedTech segment sales increased by 5.3% operationally, with Cardiovascular sales up 17.1%.
• Abiomed sales grew by 15.5% to $1.291 billion for the fiscal nine months.
• The reversal of approximately $7.0 billion in talc litigation reserves significantly boosted net earnings.
• Strong cash flow from operations of $17.221 billion for the fiscal nine months.

Negatives

• STELARA sales declined by 39.5% to $4.848 billion for the fiscal nine months due to biosimilar competition and Medicare Part D redesign, negatively impacting worldwide operational sales by approximately 6.1%.
• IMBRUVICA sales decreased by 7.3% to $2.139 billion for the fiscal nine months due to competitive pressures and Medicare Part D redesign.
• ZYTIGA sales declined by 22.8% to $383 million for the fiscal nine months due to loss of exclusivity.
• INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA sales decreased by 10.6% to $2.824 billion for the fiscal nine months due to Medicare Part D redesign.
• Orthopaedics segment sales experienced an operational decline of 0.8% for the fiscal nine months, with Spine, Sports & Other down 5.0%.
• The worldwide effective income tax rate increased to 21.5% from 16.9% due to the U.S. One Big Beautiful Bill Act (OBBBA), including a one-time re-measurement cost of approximately $1.0 billion.
• Net cash and cash equivalents decreased by $5.874 billion from December 29, 2024, to September 28, 2025.
• Total debt increased by $10 billion to $45.8 billion compared to the prior year fiscal third quarter.

Risks

• Challenges and uncertainties inherent in innovation and development of new and improved products and technologies, including clinical outcomes, regulatory approvals, health plan coverage, and commercial success.
• Challenges to the ability to secure and maintain adequate patent and other intellectual property rights, and increasingly aggressive challenges to patents by competitors.
• The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses.
• Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action, declining sales, reputational damage, increased litigation expense, and share price impact.
• The impact of significant litigation or government action adverse to the company, including product liability claims (e.g., talc, opioids, pelvic mesh) and allegations related to pharmaceutical marketing practices and contracting strategies.
• Increased scrutiny of the healthcare industry by government agencies and state attorneys general, resulting in investigations and prosecutions with potential for significant civil and criminal penalties.
• Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions.
• Potential changes to applicable laws and regulations affecting United States and international operations, including relating to approval of new products, licensing and patent rights, sales and promotion of healthcare products, access to and reimbursement and pricing for healthcare products and services, environmental protection, and sourcing of raw materials.
• Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities, potentially causing exposures to additional tax liabilities in excess of existing reserves (e.g., OBBBA, Pillar Two Directive).
• Pricing pressures resulting from trends toward healthcare cost containment, including consolidation among healthcare providers, managed care, governments as primary payors, and new market entrants.
• Challenges to the ability to realize its strategy for growth through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing, and marketing agreements, and potential heightened costs due to competitive pressures.
• The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture may not be realized or may take longer to realize than expected.
• The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.
• The ability to satisfy the necessary conditions to consummate the planned separation of the Orthopaedics business on a timely basis or at all, and to successfully separate and realize anticipated benefits.
• The risks associated with global operations, including foreign governments, inflation, fluctuations in interest rates and currency exchange rates, and potential changes in export/import and trade laws.
• The impact of global public health crises and pandemics, changes to global climate, extreme weather, natural disasters, global tensions, and war.
• Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to business interruptions, product shortages, withdrawals, or regulatory action.
• Interruptions and breaches of information technology systems or those of vendors, which could result in reputational, competitive, operational, or other business harm, as well as financial costs and regulatory action.
• Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements.

Future Outlook

The company expects continued launches of biosimilar versions of STELARA in Europe and the United States, which will impact sales. The restructuring programs for the MedTech Surgery and Orthopaedics franchises are expected to be substantially completed by the end of fiscal year 2026 and 2025, respectively. The planned separation of the Orthopaedics business is targeted for completion within 18 to 24 months after the October 14, 2025 announcement. The impact of the Inflation Reduction Act's Medicare Drug Price Negotiation Program remains uncertain due to ongoing litigation. The company anticipates that operating cash flows, external funding, credit facilities, and commercial paper markets will provide sufficient resources for operations, including remaining talc and opioid litigation settlements.

Management Comments

• We continue to believe that we have strong legal grounds to contest all the talc verdicts that we have appealed.
• Notwithstanding the Company's confidence in the safety of its talc products, in certain circumstances the Company has settled cases.
• The Company expects to continue the practice of paying regular quarterly cash dividends.
• The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs.

Industry Context

The pharmaceutical and medical technologies industries continue to face extensive regulation, government investigations, and litigation, as evidenced by ongoing talc and opioid lawsuits, as well as antitrust claims. The impact of biosimilar competition, particularly for key drugs like STELARA, is a significant trend affecting revenue. Healthcare cost containment, managed care, and government pressure on pricing (e.g., Medicare Part D redesign, Inflation Reduction Act) are ongoing challenges. The company's strategic acquisitions in areas like mental health (CAPLYTA) and cardiovascular technology (Shockwave, Abiomed) reflect a focus on high-growth, innovative segments, while the planned separation of the Orthopaedics business indicates a move towards streamlining and specialization in a competitive MedTech landscape.

Comparison to Industry Standards

• The significant decline in STELARA sales due to biosimilar competition is a common challenge faced by pharmaceutical companies as patents expire, similar to how other blockbuster drugs have seen revenue erosion post-exclusivity.
• The acquisitions of Intra-Cellular Therapies and Shockwave Medical align with a broader industry trend of M&A activity to bolster pipelines and expand market presence in high-growth therapeutic areas and medical device technologies. For example, similar to Pfizer's acquisition of Seagen to boost its oncology portfolio or Medtronic's strategic acquisitions in medical technology.
• The restructuring initiatives in MedTech's Surgery and Orthopaedics franchises reflect a common industry practice of optimizing operations and divesting non-core assets to improve efficiency and focus, comparable to similar efforts by companies like Zimmer Biomet or Stryker to streamline their orthopaedics portfolios.
• The ongoing litigation related to talc and opioids highlights the persistent legal and regulatory risks inherent in the pharmaceutical and consumer health sectors, a challenge also faced by companies like Purdue Pharma (opioids) or Bayer (Roundup litigation).

Legal Proceedings

• Talc Litigation: Approximately $7.0 billion of previously accrued talc reserves were reversed following the dismissal of the Red River Bankruptcy Case on March 31, 2025. The total present value of the reserve is now $3.8 billion. The company has returned to the tort system, with bellwether trials scheduled in California (November 2025) and New Jersey (January 2026). Appeals are ongoing regarding the Imerys Settlement Agreement.
• Opioid Litigation: Approximately 80% of the $5.0 billion state and subdivision settlement has been paid. Hospital cases were settled in September 2024. Approximately 23 remaining opioid cases are against the company and JPI in state courts, 285 in the Ohio multi-district litigation (MDL), and 3 in other federal courts. Canadian class actions are also ongoing, with an appeal scheduled for December 2025.
• Product Liability (Other): Ongoing claims for DePuy ASR Hip, PINNACLE Acetabular Cup System, Ethicon Pelvic Mesh, Ethicon Physiomesh, PROCEED Mesh, PROCEED Ventral Patch, PROLENE Polypropylene Hernia System, and ELMIRON. Accruals have been established for these matters.
• Intellectual Property: Lawsuits against generic manufacturers for XARELTO, INVEGA SUSTENNA, ERLEADA, SPRAVATO, CAPLYTA, and UPTRAVI patents are ongoing. The Federal Circuit affirmed the district court ruling of no invalidity for INVEGA SUSTENNA patent 9,439,906 in July 2025. A confidential settlement was reached with Lupin parties for ERLEADA in August 2025. A confidential settlement was reached with Hetero parties for CAPLYTA in July 2025.
• Government Proceedings: A DOJ civil investigation under the False Claims Act related to J&J Vision's intraocular lenses and equipment is ongoing. A qui tam False Claims Act complaint against Janssen Products, LP regarding off-label promotion of HIV products (PREZISTA, INTELENCE) resulted in a jury finding of liability for a portion of off-label claims in June 2024, which the company is appealing.
• General Litigation: A complaint against the company and certain subsidiaries alleging violation of the U.S. Anti-Terrorism Act related to sales practices in Iraq is remanded to the D.C. Circuit. A putative class action alleging breach of fiduciary duties under ERISA related to the company's prescription-drug benefits program is ongoing.
• MedTech Litigation: The Delaware Court of Chancery found liability against Ethicon Inc. for certain claims in connection with the acquisition of Auris Health Inc., which the company is appealing. A jury verdict in favor of Innovative Health against Biosense Webster, Inc. for antitrust violations was appealed by BWI.
• Innovative Medicine Litigation: An antitrust class action against Actelion Pharmaceutical Ltd. regarding TRACLEER samples is scheduled for trial in March 2026. A putative class action lawsuit against Janssen Biotech Inc. alleging antitrust violations for delaying biosimilar competition with STELARA is ongoing. A qui tam complaint against Janssen regarding ZYTIGA pricing information is ongoing.

Stakeholder Impact

• Shareholders: Experienced a significant increase in net earnings and EPS (though largely due to a one-time event), continued to receive regular quarterly cash dividends, and benefited from an ongoing share repurchase program. Potential for long-term value creation from strategic acquisitions and the Orthopaedics separation, but also face risks from ongoing litigation and biosimilar competition.
• Employees: Restructuring programs in the MedTech Surgery and Orthopaedics franchises may impact employees through optimization of sites and exiting product lines.
• Customers: Benefit from the continued availability of innovative medicines and medical technologies. The impact of Medicare Part D redesign and potential drug price negotiations under the IRA could affect access and costs.
• Suppliers: The company has supplier finance programs in place, with confirmed obligations of $0.6 billion as of September 28, 2025.
• Creditors: The company's increased long-term debt to fund acquisitions is supported by strong operating cash flows and access to credit facilities, providing liquidity.

Next Steps

• Continue to litigate talc claims in the tort system, with bellwether trials scheduled in California (November 2025) and New Jersey (January 2026).
• Continue the confirmation hearing for the Imerys and Cyprus Chapter 11 plans, scheduled to continue the week of February 2, 2026.
• Proceed with the planned separation of the Orthopaedics business, targeting completion within 18 to 24 months after October 14, 2025.
• Substantially complete the MedTech Surgery franchise restructuring program by the end of fiscal year 2026.
• Substantially complete the MedTech Orthopaedics franchise restructuring program by the end of fiscal year 2025.
• Monitor further developments regarding the EU's Pillar Two Directive and potential impacts on the effective tax rate.
• Continue to monitor and assess the effectiveness of disclosure controls and procedures and align/streamline financial control environment.

Key Dates

Recommendation

While the reported net earnings show a substantial increase, this is primarily driven by a one-time reversal of talc litigation reserves rather than core operational growth. The company demonstrates solid operational sales growth in key segments like Innovative Medicine (Oncology, Neuroscience) and MedTech (Cardiovascular), bolstered by strategic acquisitions. However, significant headwinds from STELARA biosimilar competition and increased debt levels warrant caution. The planned separation of the Orthopaedics business presents a strategic opportunity but also introduces execution risks and uncertainty. Given the mixed financial performance, ongoing litigation risks, and the transformative nature of the announced separation, a 'hold' recommendation is appropriate for investors to observe the execution of strategic initiatives and the impact of competitive and regulatory pressures.

Keywords

Pharmaceuticals, Medical Devices, Healthcare, Biotechnology, Oncology, Immunology, Neuroscience, Cardiovascular, MedTech, Orthopaedics, Talc Litigation, Opioid Litigation, SEC Filing, Earnings Report, Acquisitions, Divestitures, Restructuring, STELARA Biosimilar, CAPLYTA, Shockwave Medical, Johnson & Johnson